Vivoryon Therapeutics N.V. Stock
Stocks
VVY
NL00150002Q7
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Amsterdam
19:55:00 28/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 1.100 EUR | -0.90% |
|
+1.38% | -22.54% |
| 08-07 | Vivoryon Therapeutics N.V., H1 2026 Earnings Call, Aug 06, 2026 | |
| 08-06 | Vivoryon Therapeutics N.V. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| Market Cap | 32.58M 37.04M 30.8M 27.94M 52.47M 3.56B 52.78M 369M 142M 1.81B 139M 136M 5.83B | P/E 2026 * |
-2.89x | P/E 2027 * | -2.97x |
|---|---|---|---|---|---|
| Enterprise Value | 36.9M 41.95M 34.89M 31.65M 59.43M 4.03B 59.78M 418M 161M 2.05B 158M 154M 6.6B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
82.01% | Yield 2026 * |
-
| Yield 2027 * | - |
Euronext AmsterdamEUR
| Markets | Quality | ||
|---|---|---|---|
Euronext Amsterdam
| VVY | Real-time | |
Tradegate
| 05Y | Real-time | |
|
CBOE
| VVY | Real-time | |
|
Boerse Muenchen
| 05Y | Real-time | |
|
Deutsche Boerse AG
| 05Y | Delayed | |
|
CBOE
| 0R3M | Real-time | |
|
Börse Stuttgart
| 05Y | Delayed | |
|
Wiener Boerse
| VVYN | End-of-day quote |
Last Transcript: Vivoryon Therapeutics N.V.
| 1 day | -0.90% | ||
| 1 week | +1.38% | ||
| Current month | -2.65% | ||
| 1 month | -3.08% | ||
| 3 months | +1.85% | ||
| 6 months | -16.03% | ||
| Current year | -22.54% |
| 1 week | 1.08 |  | 1.12 |
| 1 month | 1.07 | | 1.14 |
| Current year | 1 | | 1.65 |
| 1 year | 1 | | 1.84 |
| 3 years | 0.41 | | 11.68 |
| 5 years | 0.41 | | 20.77 |
| 10 years | 0.41 | | 23.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 66 | 14/08/2023 |
Anne Doering
DFI | Director of Finance/CFO | - | 01/03/2024 |
Julia Neugebauer
COO | Chief Operating Officer | - | 01/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 56 | 01/01/2007 | |
Frank Weber
BRD | Director/Board Member | 66 | 15/09/2023 |
| Director/Board Member | 58 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 23/10/25 | Free | Chief Operating Officer | 20,000 | 0.0767% | ||
| 23/10/25 | Buy | Chief Executive Officer | 135,000 | 0.5179% | ||
| 23/10/25 | Free | 20,000 | 0.0767% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.90% | +1.38% | -32.10% | -90.25% | 37.46M | |
| +2.64% | +6.45% | +11.87% | +38.40% | 47.97B | |
| +0.22% | +0.40% | +50.91% | +37.06% | 44.5B | |
| -1.58% | +4.66% | +359.34% | +614.38% | 43.93B | |
| +1.70% | +0.36% | +12.56% | +99.27% | 41.03B | |
| +0.51% | -1.71% | +5.18% | +46.87% | 29.85B | |
| -0.48% | -1.32% | +23.98% | +150.01% | 17.27B | |
| +0.08% | +9.03% | +8.41% | - | 15.34B | |
| +1.76% | +0.85% | +29.13% | +48.42% | 15.3B | |
| +1.97% | -3.17% | - | - | 14.82B | |
| Average | +0.59% | +1.61% | +52.14% | +118.02% | 27.01B | |
| Weighted average by Cap. | +0.74% | +1.89% | +79.45% | +163.75% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -10.4M -11.82M -9.83M -8.92M -16.75M -1.14B -16.85M -118M -45.48M -579M -44.4M -43.43M -1.86B | -10.4M -11.82M -9.83M -8.92M -16.75M -1.14B -16.85M -118M -45.48M -579M -44.4M -43.43M -1.86B |
| Net Debt | 4.32M 4.91M 4.09M 3.71M 6.96M 471M 7M 48.91M 18.89M 241M 18.44M 18.04M 773M | 13.03M 14.82M 12.32M 11.18M 20.99M 1.42B 21.11M 148M 56.98M 726M 55.62M 54.42M 2.33B |
Employees
13
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/09/26 | €1.100 | -0.90% | 9,930 |
| 25/09/26 | €1.110 | 0.00% | 8,828 |
| 24/09/26 | €1.110 | +0.91% | 21,919 |
| 23/09/26 | €1.100 | +1.85% | 25,986 |
| 22/09/26 | €1.080 | -0.46% | 52,818 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.100EUR
Average target price
6.850EUR
Spread / Average Target
+522.73%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VVY Stock
Select your edition
All financial news and data tailored to specific country editions
